To examine whether FGFR4 expression correlates with intrinsic anti-HER2 resistance, we performed IHC staining using 36 HER2-positive breast cancer biopsies obtained before administration of anti-HER2 based neoadjuvant therapy (Fig. 1j). Here, FGFR4 is linked to breast carcinoma.